MARBOCYL 10 % SOLUTION FOR INJECTION
Nchi: Ayalandi
Lugha: Kiingereza
Chanzo: HPRA (Health Products Regulatory Authority)
Tabia za bidhaa
(SPC)
04-11-2016
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
MARBOFLOXACIN
Inapatikana kutoka:
Vetoquinol Ireland Limited
ATC kanuni:
QJ01MA93
INN (Jina la Kimataifa):
MARBOFLOXACIN
Kipimo:
10 %w/v
Dawa fomu:
Solution for Injection
Dawa ya aina:
POM
Kundi la matibabu:
Bovine, Porcine
Eneo la matibabu:
Marbofloxacin
Matibabu dalili:
Antibacterial
Idhini hali ya:
Authorised
Idhini ya tarehe:
1997-10-31
Tabia za bidhaa
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Marbocyl 10% Solution for Injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Solution for injection.
Clear, yellow to green/brown solution
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle and pigs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In Cattle
Marbofloxacin 10% injection is indicated in the treatment of respiratory infections caused by susceptible strains of
organisms. It is also indicated in the treatment of acute _E.coli _mastitis.
In Pigs
Marbofloxacin 10% injection is indicated in the treatment of Metritis Mastitis Agalactia syndrome caused by
susceptible strains of organisms
4.3 CONTRAINDICATIONS
None known
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None known
Active Substance:
Marbofloxacin
100 mg
Excipients:
m-Cresol
2.0 mg
Monothioglycerol
1.0 mg
Disodium Edetate
0.1 mg
Excipient Q.S.
1
ml
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 19/10/2016_
_CRN 7023455_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Official and local antimicrobial policies should be taken into account when the product is used.
Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected
to respond poorly, to other classes of antimicrobials.
Whenever possible, fluoroquinolones should only be used based on susceptibility testing.
Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to
fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potent
Soma hati kamili
